Search

Jardiance® Recommended as Preferred SGLT2 Inhibitor for Adults with Type 2 Diabetes and Established Cardiovascular Disease in American College of Cardiology Expert Consensus Decision Pathway

Full data announced in phase III EMPA-KIDNEY trial

The EMPA-KIDNEY phase III clinical trial met its primary endpoint by demonstrating a significant kidney and cardiovascular benefit for adults living with chronic kidney disease (CKD)

U.S. FDA approves Jardiance® (empagliflozin) tablets to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease

U.S. FDA approves Synjardy® (empagliflozin/metformin hydrochloride) tablets for adults with type 2 diabetes

A grandmother’s empathy offers a safe space for people with mental health conditions

Supporting the Friendship Bench to improve access to mental healthcare.

200 employees make a difference with record-breaking volunteer efforts

Flying animals to safety with Greater Good Charities

Watch as Julie Ryan-Johnson volunteers to take care of animals being brought to new homes following the Maui wildfires.

Discover your hidden talent with BI Open – the new platform for data science enthusiasts

Discover your hidden talent with BI Open – the new platform for data science enthusiasts. For more talent insights, visit our Careers Page.

Growing with us

We recognize the benefits of learning and have created an environment where life-long learning and personal growth are encouraged for all employees.

Our Work with the Gates Foundation | COVID-19 | Boehringer Ingelheim US

With global life science companies, we are joining the COVID-19 Therapeutics Accelerator of the Bill & Melinda Gates Foundation to fight the pandemic.

3 Ways Boehringer Ingelheim's Corporate Values Align with Hispanic Heritage

Annual Declaration of Boehringer Ingelheim Corporation’s compliance with its Comprehensive Compliance Program.

Boehringer Ingelheim enters into collaboration with Roche to partner for inflammatory bowel diseases

Boehringer Ingelheim announces InPedILD PhaseIII trial results

Our evolved employer value proposition

Find out from a father-daughter duo how we live up to our people promise and how our company identifies itself and differentiates from other employers.

Dan’s Unique Story

Each cancer journey is unique. In 2018 Dan was diagnosed with a rare form of sarcoma called dedifferentiated liposarcoma. Learn more about Dan’s unique approach to life with DDLPS.

Generalized Pustular Psoriasis: Impact Beyond the Skin

Generalized pustular psoriasis (GPP) is not only about the physical symptoms that impact people living with the condition. GPP goes deeper, beyond the skin.

Results from Phase II MASH trial announced at EASL 2024

Boehringer Ingelheim announced results from Phase II trial in metabolic dysfunction-associated steatohepatitis (MASH) at EASL 2024

Sarcoma: An expert’s perspective

Gary Schwartz, MD, Director of the Case Comprehensive Cancer Center, Cleveland, Ohio, shares his expert perspectives on sarcoma, the importance of early detection, and his hopes for the sarcoma treatment landscape.

Fostering Science | Boehringer Ingelheim US

Find out how creating breakthrough medicines to change patients’ lives starts with a commitment to identify the challenges of the future & emerging science.

Look Beyond Stable Video

Learn more about Look Beyond Stable campaign from the perspectives of people living with schizophrenia and others.

Obesity

New agreement with Quallent expands biosimilar access

Boehringer Ingelheim enters private label agreement for biosimilar

Cyltezo® (adalimumab-adbm): First Interchangeable Biosimilar | BI US

Read more about how the FDA have approved CYLTEZO as the first interchangeable biosimilar with Humira®, supported by data from BI’s Phase III clinical trial.

New affordability initiative with GoodRx for our biosimilar

Boehringer Ingelheim announces patient affordability initiative with GoodRx for biosimilar

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers